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ABSTRACT
Objectives: (1) To explain general practitioners’
(GPs’) approaches to prostate-specific antigen (PSA)
testing and overdiagnosis; (2) to explain how GPs
reason about their PSA testing routines and (3) to
explain how these routines influence GPs’ personal
experience as clinicians.
Setting: Primary care practices in Australia including
men’s health clinics and rural practices with variable
access to urology services.
Participants: 32 urban and rural GPs within Australia.
We included GPs of varying ages, gender (11 female),
clinical experience and patient populations. All GPs
interested in participating in the study were included.
Primary and secondary outcome measure(s):
Data were analysed using grounded theory methods to
determine how and why GPs provide (or do not provide)
PSA testing to their asymptomatic male patients.
Results: We observed patterned variation in GP
practice, and identified four heuristics to describe GP
preference for, and approaches to, PSA testing and
overdiagnosis: (1) GPs who prioritised avoiding
underdiagnosis, (2) GPs who weighed underdiagnosis
and overdiagnosis case by case, (3) GPs who prioritised
avoiding overdiagnosis and (4) GPs who did not engage
with overdiagnosis at all. The heuristics guided GPs’
Routine Practice (usual testing, communication and
responses to patient request). The heuristics also
reflected GPs’ different Practice Rationales (drawing on
experience, medicolegal obligations, guidelines and
evidence) and produced different Practice Outcomes
(GPs’ experiences of the consequences of their PSA
testing decisions). Some of these heuristics were more
responsive to patient preferences than others.
Conclusions: Variation in GPs’ PSA testing practices is
strongly related to their approach to overdiagnosis and
underdiagnosis of prostate cancer. Men receive very
different care depending on their GP’s reasoning and
practice preferences. Future policy to address
overdiagnosis will be more likely to succeed if it
responds to these patterned variations.
INTRODUCTION
Prostate-speciﬁc antigen (PSA) testing for
prostate cancer in healthy men is an
emotive, controversial1 and hotly debated
issue. Evidence suggests that harms of PSA
testing for prostate cancer in asymptomatic
men can outweigh beneﬁts.2–4 Most guide-
lines recommend against population screen-
ing;3 5–7 however, some professional societies
do recommend selective PSA testing8–10
(table 1). In Australia, and internationally,
many men continue to be tested despite
guidelines advising not to screen.16–18 This
article presents an empirical qualitative study
of how Australian general practitioners (GPs)
reason about PSA testing of asymptomatic
men for prostate cancer, who they test and
why, with a particular focus on how GPs
manage the risk of overdiagnosis.
Overdiagnosis and/or overtreatment are
considered the main potential harms of PSA
testing. Overdiagnosis occurs when people
without symptoms are correctly diagnosed
Strengths and limitations of this study
▪ Most previous research has examined which
general practitioner (GP) characteristics are asso-
ciated with frequent or infrequent testing, and
has been predominantly quantitative. This
in-depth qualitative study offers a unique exam-
ination of GPs’ approaches to prostate cancer
overdiagnosis, from the GP perspective. It is the
first study to systematically map prostate-specific
antigen (PSA) testing with GPs’ reasoning and
understanding of prostate cancer screening and
overdiagnosis.
▪ We identified and interviewed highly informative
participants (GPs) and have developed valuable
detailed insights into how the PSA testing
process works in everyday practice.
▪ There may be value in knowing the prevalence of
the four heuristics we have discovered across the
population: a next step could be a population-
based survey to ascertain the prevalence of these
heuristics at a population level.
▪ Since physicians with strong opinions may have
been more likely to volunteer, some selection
bias is possible. However, diverse opinions and
approaches were reported, suggesting that
strong selection bias is unlikely.
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Table 1 The US, UK and Australian recommendations for prostate-specific antigen (PSA) testing of asymptomatic men for
prostate cancer
Professional body
Advice for health practitioners (see original documents for exact
phrasing)
Population US Preventive Services Task Force
(USPSTF)3
▸ Discuss PSA screening thoroughly with men who raise the issue or
if the man’s individual circumstances warrant consideration of PSA
testing. Do not feel obligated to offer PSA testing if a patient does
not raise the issue or request the test
▸ The decision to start or continue PSA screening should reflect the
patient’s understanding of the possible benefits and expected harms
and should respect his preferences
National Health and Medical
Research Council (NHMRC)11
▸ Before ordering a PSA test, health practitioners should talk to men
about the potential benefits and harms of PSA testing
National Health Service (NHS)12 ▸ Screening not recommended. An informed choice programme,
Prostate Cancer Risk Management aims to provide high-quality
information about the risks and benefits to men who ask about
screening in order to enable them to decide whether to have the test
National American Cancer Society (ACS)10 ▸ Provide men the opportunity to make an informed decision; for men
who are unable to decide, the screening decision can be left to the
discretion of the healthcare provider
▸ Men at average risk and expected to live at least 10 more years
should receive this information beginning at age 50 years. Men in
higher risk groups should receive this information at age 40–
45 years
Cancer Council Australia (CCA) and
Australian Health Ministers’ Advisory
Council (AHMAC), 2010*13
▸ Speak to men about the benefits and harms of testing and treatment
so that they can make an informed choice
Specialist American Urological Association
(AUA)8
▸ Shared decision-making for men aged 55–69 years based on a
man’s values and preferences
▸ Routine screening is not recommended in men aged 40–54 years at
average risk, or in men over 70 years or with less than a 10–15-year
life expectancy; decisions should be individualised for men younger
than 55 years at higher risk
Urological Society of Australia and
New Zealand (USANZ)14
▸ PSA and digital rectal examination (DRE) should be offered to men
55–69 years, after providing information about the risks and benefits
of such testing
▸ Interested men in younger age groups (under 55 years) could have a
single PSA test and DRE performed at or beyond age 40 to provide
an estimate of their prostate cancer risk over the next 10–20 years,
with the intensity of subsequent monitoring being individualised
accordingly
Primary
Care
American College of Physicians
(ACP)15
▸ Inform men 50–69 years about the limited potential benefits and
substantial harms of screening for prostate cancer
▸ Base the decision on the man’s risk for prostate cancer, a
discussion of the benefits and harms of screening, the patient’s
general health and life expectancy and patient preferences
▸ Advised not to screen patients who do not express a clear
preference for screening
▸ Advised not to screen average-risk men under 50 years, over
69 years, or with a life expectancy of less than 10 to 15 years
Royal Australian College of General
Practitioners (RACGP)6
▸ Not recommended unless the man specifically asks for it, and he is
fully counselled on the pros and cons
▸ General practitioners need not raise this issue, but if men ask about
prostate screening they need to be fully informed of the potential
benefits, risks and uncertainties of prostate cancer testing
▸ When a patient chooses screening, both PSA and DRE should be
performed
▸ Responding to the patient’s concerns and fulfilling medicolegal
responsibilities are considerations in discussion with patients
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with a disease that would not cause them to experience
symptoms or early death.19 It is hard to understand and
explain,20 and difﬁcult to quantify; estimates range from
15% to more than 84% of screen-detected prostate
cancers.21–26 Overdiagnosis may lead to overtreatment:27
treatment a person did not need. PSA testing often trig-
gers a cascade of diagnostic tests and active treat-
ment,28 29 potentially compromising a well person’s
quality of life.30 31 Advocates of testing argue that PSA
testing may, in some cases, lower the stage and grade of
cancer at diagnosis, and reduce the risk of being diag-
nosed with metastatic prostate cancer, for which there is
no cure.32–34 However, across the population of asymp-
tomatic men, PSA testing does not decrease all-cause
mortality, and some men will progress and develop meta-
static disease even if they are screened (despite earlier
diagnosis).35
Responsibility for guiding men’s decisions about
whether or not to be screened for prostate cancer has
largely been placed in the hands of individual physi-
cians. In Australia, GPs are the primary point of
contact to access a PSA test. There is no organised
screening programme; PSA testing is opportunistic but
prevalent.18
Empirical work exploring prostate cancer screening in
general practice has primarily focused on: (1) the
reasons GPs give for ordering PSA tests; (2) the
characteristics of GPs (such as age, gender, location)
associated with more or less frequent testing and
(3) how GPs communicate with patients about the PSA
test.36–44 The predominantly quantitative evidence pro-
vides insights into the patterns and potential drivers of
PSA testing in general practice but does not illuminate
the dilemmas of PSA testing from the GP’s perspective,
and in particular how GPs reason about overdiagnosis.
To ﬁll this gap, we conducted a qualitative study to
explore how and why GPs provide (or do not provide)
PSA testing to their asymptomatic male patients. We
report on the signiﬁcance and impact of overdiagnosis
in GPs’ clinical reasoning about PSA testing.
METHODS
Design
We used the well-established, systematic qualitative
research methodology of grounded theory45 to guide
our sampling and analysis. We collected data via
in-depth interviews. GPs had an opportunity to discuss
the study, and gave consent prior to participation.
Participants and setting
We recruited 32 urban and rural GPs throughout
Australia (11 female). Our initial purposive sample was
of GPs working in men’s health clinics in Sydney (n=2).
We advertised via the newsletters and email lists of
regional GP organisations (Medicare Locals) in Sydney
(n=8). GPs were invited to contact KP if they were inter-
ested and willing to participate in the research. We then
broadened our sampling by advertising in mass and
social media, and in medical journals (Medical Observer,
the Australian Medical Association’s GP Network News,
and the 6 min newsletter). As analysis and sampling
evolved, we invited additional rural and interstate GPs to
answer speciﬁc analytical questions (n=11). Rural GPs
were accessed by phoning practice managers, through
colleagues, and advertising with rural Medicare Locals,
adding eight further GPs. When we encountered GPs
whose routine care was divergent from previously inter-
viewed GP norms, we invited more GPs from that prac-
tice to attempt to distinguish between personal and
institutional inﬂuences on their practice. An additional
three GPs were recruited in this ﬁnal phase of theoret-
ical sampling. GPs of varying ages, clinical experience,
gender and patient populations were all included. All
GPs interested in participating in the study were
included. GPs were compensated for their time.
Interviews/data collection
A semistructured interview schedule was developed with
a focus on GPs’ current approaches to, and reasoning
about, PSA testing. The schedule covered a broad range
of topics, including GPs’ recent clinical encounters
involving PSA testing decisions; communicating informa-
tion; screening pathways; and the central theme of this
paper, overdiagnosis. The interview schedule was modi-
ﬁed between interviews, informed by the developing
analysis. Interviews took place between March and
September 2013. They were conducted by KP, mostly by
telephone, and ranged in duration from 18 min to 1 h
and 10 min. All interviews were audio-recorded,
de-identiﬁed and transcribed verbatim.
Examples of questions GPs were asked about overdiag-
nosis included the following:
▸ Are you familiar with the term ‘overdiagnosis’?
▸ Do you think about the issue of overdiagnosis in your
practice?
▸ How do you manage overdiagnosis in your practice?
▸ Overdiagnosis must be a challenging concept to talk
about with your patients; how do you manage that
challenge?
Data coding and analysis
The analysis was led by KP, who coded the transcripts
and wrote detailed memos which were reviewed and dis-
cussed by the authors in analytical meetings. A subset of
transcripts was read and coded by all three authors inde-
pendently; this coding was compared and discussed to
inform the development of the central concepts in the
study. This paper focuses on how GPs dealt with the
concept of overdiagnosis.
RESULTS
Most GPs felt uncertain and/or conﬂicted regarding
what to do about PSA testing of asymptomatic men.
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In the following section, we will explain overall patterns
and then outline four heuristics used in practice.
GPs considered underdiagnosis as well as overdiagnosis
GPs discussed the harms of underdiagnosis (the missed
opportunity to intervene in potentially preventable
deaths) as much as those of overdiagnosis (the psycho-
logical and physical harms and ﬁnancial costs of
unnecessary diagnosis and treatment). Since both harms
are salient and serious, PSA testing decisions were
described as a “balancing act” (GP21) or gamble. GPs
reported the difﬁculties of needing to choose between
potential harms (eg, incontinence and impotence) and
the chance of saving lives.
Testing decisions were described as a personal burden
Uncertainty about PSA testing created a ‘personal
burden’ for some GPs; they felt personally responsible
for the consequences of their PSA testing approach, and
experienced guilt and self-blame as a result.
Many GPs used personal or professional experiences
with the PSA test, both positive and negative, as powerful
anchors for their current practice: these experiences
often explained GPs’ perception of personal burden. We
will return to the personal burden of PSA testing
throughout the following sections.
GPs’ communication practices varied
GPs varied in the conversations they had with men spe-
ciﬁcally about overdiagnosis. Some deliberately avoided
raising the issue, or talked men into or out of having a
PSA test. GPs described several important contextualis-
ing factors.
1. Cancer is widely feared and difﬁcult to talk about.
2. Overdiagnosis is hard to understand for GPs and for
the public—and it is contradictory to many people’s
existing health beliefs.
3. Both doctors and patients often have a strong belief
that cancer screening is, in general, a worthwhile and
important strategy to combat the risk of getting
cancer.
GPs employed four heuristics to manage PSA testing
GPs’ responses to this difﬁcult situation depended on
how they viewed an implicit continuum between over-
diagnosis and underdiagnosis. They considered which
end of the spectrum would cause the greatest harm to
each patient and/or their patients in general.
Four broad patterns (‘heuristics’) were employed.
1. Some GPs preferred to offer PSA testing to avoid
underdiagnosis.
2. Some GPs were strongly oriented to avoiding over-
diagnosis, and so tried to test as little as possible.
3. Some GPs made case-by-case individualised decisions.
4. Some GPs did not think about underdiagnosis or
overdiagnosis at all.
These four heuristics represent observed patterns of
GPs’ preferred or dominant practice orientations; that is, each
GP seemed to prefer one of these four heuristics as their
overall approach to PSA testing. Some of these heuristics
were more responsive to patient preferences than others
(table 2).
The GPs’ Dominant Practice Orientation guided their
Routine Practice (usual testing, communication and
responses to patient requests). GPs also described their
Practice Rationale (drawing on experience, medicolegal
obligations, guidelines and evidence) which inﬂuenced
testing decisions and justiﬁed why they adopted their
particular practice orientation. Their orientation pro-
duced a Practice Outcome: GPs’ experiences of the conse-
quences of their PSA testing decisions. The four
dominant practice orientations (heuristics) are sum-
marised in table 2 and described below.
Heuristic 1: GP preference to offer PSA testing to avoid
underdiagnosis
GPs employing heuristic 1 thought testing was necessary
because there was a possibility it might prevent a man’s
death. Overdiagnosis was perceived as (1) a natural con-
sequence of PSA testing; (2) better than dying and (3) a
justiﬁable source of harm (harms being a regrettable
but necessary price of ‘cure’).
These GPs focused on cancer as life-threatening, and
prostate cancer as a terrible death. They saw preventing
death as the primary duty of the GP. This heightened
their responsibility to do anything that may diagnose
cancer early: “Because if you don’t overdiagnose, the
alternative is to underdiagnose” (GP28). Underdiagnosis
was perceived to be a medicolegal risk, and for some
GPs, legal risk was uppermost in their minds during the
decision-making process. GPs concerned with missing
diagnosing cancers practised more defensively; “I’m
often a bit defensive…I guess that’s partly that legal
thing” (GP5).
GPs with this practice orientation advised men to have
a PSA, emphasising beneﬁts of early detection, and did
not discuss overdiagnosis.
Some of these GPs thought decisions about postdiagno-
sis management (eg, active surveillance) could limit the
harms of potential overdiagnosis. This allowed them to
deﬁne testing without invasive procedures as inconse-
quential: “it’s not terribly onerous to have a blood test
every six months” (GP3). Although many of these GPs
accepted that the PSA test was not perfect, they preferred
to test because “clearly, people’s lives are saved” (GP8).
These GPs anchored their practice orientation to per-
sonal experiences. Their approach was supported by
stories of men still being alive following active testing
and treatment.
Another anchor for this heuristic was having experi-
enced caring for patients with metastatic cancers, “I’ve
had two recently where their GP refused to actually test
the PSA level over the last ten years and both presented
with metastatic prostate cancer” (GP24), and witnessing
the horrors of prostate cancer deaths: “dying from pros-
tate cancer would probably rank amongst one of the
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worst ways to die…pain that is almost not able to be alle-
viated by narcotics” (GP29).
Despite their convictions, GPs experienced some per-
sonal struggle when they witnessed side effects of pros-
tate cancer treatment. Such cases were often recalled in
detail. For example, one GP describes this as “a heavy
burden if a person is left with side effects” but accepted
that “that’s just part of being a GP, you have to walk
around with this” (GP29). They tried not to take it per-
sonally, “oh, well, it happens. I mean, unfortunately, no
matter how good a doctor [I am], now and then this is
going to happen” (GP19). Overall, though, the personal
burden felt by this group was relatively small and did not
challenge the GP’s belief in PSA testing, which they said
fulﬁlled their role as a clinician to save lives. Many also
regarded testing as consistent with specialists’ advice,
which allowed them to reduce their personal burden;
that is, the responsibility of decisions about PSA testing
was shared with these specialists (but not with their
patients).
Heuristic 2: GP preference to not offer PSA testing to avoid
overdiagnosis
GPs employing heuristic 2 preferred not to conduct PSA
testing. Their primary justiﬁcation was preventing harms
caused by overdiagnosis. However, while they would try
to talk patients out of having the test, they would never
refuse a PSA test. These GPs also recognised that PSA
testing has saved lives; “we know that happens. The
problem is, it just doesn’t happen often enough to
balance out…all the damage that we do” (GP17).
This group of GPs emphasised the harms of PSA
testing (including overdiagnosis) when advising their
patients; and said many patients chose not to be tested
following discussion. These GPs, who fully explain over-
diagnosis, described themselves as “taking the risk of
doing the hard work, hard yards” (GP23). They resisted
medicolegal fears by engaging in detailed discussions of
beneﬁts and harms, and felt covered from legal prosecu-
tion by the Royal Australian College of General
Practitioners (RACGP) guidelines.
GPs committed to avoiding overdiagnosis particularly
drew on and trusted the research evidence to guide and
inform their testing decisions. However, practising
accordingly could be compromised by situational
factors, such as a patient who had not been tested dying
of prostate cancer. GPs said it was incredibly challenging
to ignore personal (anecdotal) experiences, yet some
were adamant that their practice would not be inﬂu-
enced by these experiences.
GPs found it hard knowing some cancers would be
missed because of their decision not to test: for
example, one described this as “a burden that I carry”
(GP8). GPs most concerned about overdiagnosis experi-
enced the highest levels of personal burden because,
although relatively rare, death as the potential conse-
quence of not testing was seen as the worst possible
outcome. Some suspected that overdiagnosis and
overtreatment were not as much of a burden for the
patient as they were for the doctor.
Heuristic 3: GP thinks of each patient as an individual
and makes case-by-case decisions
GPs employing heuristic 3 had no preconceived attitude
towards avoiding underdiagnosis or overdiagnosis. They
tailored PSA testing decisions speciﬁcally for the per-
sonal circumstances of each patient, according to the
patient’s risk proﬁle (age, family history), life expect-
ancy, interest, motivation, reason for wanting a PSA test,
cancer anxiety, or intention and ability to act on abnor-
mal test results. These GPs were particularly responsive
to patients’ individual preferences, so the outcome of
the consultation was largely unpredictable: “You have to
try and work out what’s best for the—that one particular
patient that you are talking to at the time” (GP18).
Testing ‘rules’ shifted according to the patient and the
GP; “it’s so easy to just learn what you do from a book
but once you are actually faced with someone you know
you can’t—it’s difﬁcult to apply the same rule” (GP6).
These GPs approached communication in several dif-
ferent ways. Some made their own decision about the
‘right’ approach for each particular patient, and advised
that patient accordingly. This could include not discuss-
ing overdiagnosis at all, on the grounds that it was irre-
sponsible to expect patients to understand complex
information; “if you start going down that road and—
and to what end?” (GP7). Other GPs tailored their dis-
cussion about overdiagnosis to the needs of the individ-
ual patient, their perceived level of understanding and
time pressures: “it gets more complicated depending on
how interested the person is” (GP4). Thus, the GP’s
communication depended entirely on the individual
patient in front of them.
GPs who approached PSA testing case by case gener-
ally agreed that overdiagnosis statistics do not, or cannot,
apply to individuals; “those like statistical issues don’t
apply to the individual…because…they make their deci-
sions on a set of complex, but perhaps irrational basis,
you know, anxiety and…” (GP7). Accordingly, they tai-
lored their testing and patient communication but
expressed some difﬁculties in translating population-
based information to individuals.
The personal burden experienced by these GPs was
minimal as in most consultations the burden of decision-
making was shared with their patients. GPs sought to
reach a mutual understanding of PSA testing if they
thought the patient was able to understand the informa-
tion required, and shared the responsibility of decisions
and outcomes of the consultation with the individual
man. They tended to consider decisions about PSA
testing as neither right nor wrong and so could be
swayed either way depending on the patient and their
needs. These GPs had minimal legal concern because
they perceived patients to have made informed decisions
based on their individual needs.
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Heuristic 4: GP preference to avoid thinking about
underdiagnosis or overdiagnosis
GPs not thinking about underdiagnosis or overdiagnosis
did not have a preference or priority for avoiding one
harm over another. For these GPs, the PSA test was con-
sidered just another form of routine screening and
underdiagnosis or overdiagnosis was not an issue of
concern.
The majority of GPs in this group did not engage with
considering the implications of underdiagnosis or over-
diagnosis and what that meant for their patients. Some
of these GPs felt explaining overdiagnosis was the
responsibility of urologists, and preferred to simply
inform men that a PSA test may lead to them having a
biopsy. These GPs also said they preferred to be guided
by urologists on what to do about PSA testing overall.
Personal burden associated with underdiagnosis or
overdiagnosis was therefore not a signiﬁcant feature for
this group of GPs. For some, their priority was being
regarded as a ‘good’ GP by their patients: they focused
on how their testing decisions might inﬂuence their
reputation and rapport with their patient. They reported
that a ‘good’ GP was in many cases deemed to be
someone who actively tested.
DISCUSSION
Overdiagnosis of indolent cancers in cancer screening is
now recognised as a signiﬁcant problem, but solutions to
this problem (eg, communication, public awareness) are
as yet uncertain, including in primary care. Most previ-
ous research has examined associations between GP
characteristics and frequency of PSA testing. Fewer
studies have sought to explain variation in GPs’ PSA
testing practice. Ilic and colleagues46 differentiated
‘reactive screeners’ (GPs who screened only at the
patient’s request) from ‘proactive screeners’ (GPs moti-
vated to test, believed screening was beneﬁcial, and
feared missing cancer, including for medicolegal
reasons). Our study provides a more nuanced analysis of
how and why GPs test the way they do, and offers a
unique examination of GPs’ approaches to prostate
cancer underdiagnosis and overdiagnosis. It is the ﬁrst
study to systematically examine the relationship between
GPs’ reasoning and behaviour in relation to PSA testing.
We identiﬁed four distinct approaches, each associated
with different practices, rationales and outcomes. Our
ﬁndings explain why men so often receive different
advice and clinical care: this depends on their GP’s PSA
testing practice orientation.
There is value in understanding the reasoning behind
actual practice. GPs’ reasoning makes sense of variation
in practice: it explains why different GPs are making dif-
ferent testing decisions in similar cases. GPs’ experiences
with PSA testing (positive and negative), values, percep-
tions (of the GP role, the patient role, of the PSA test
and overdiagnosis), considerations of evidence and
guidelines, and their sense of personal burden
(anticipated or experienced) all uniquely contribute to
PSA testing patterns. Variation in practice has ethical
implications, as men are experiencing unequal access to
information and consent to PSA testing. Yet these GPs
were not acting arbitrarily; most were simply doing the
best they could in an almost impossible situation. The
difﬁcult position GPs are in should be recognised in
future efforts to address the problem of prostate cancer
overdiagnosis.
Policy implications
Guidance used by Australian GPs about PSA testing
varies widely (see table 1). This also contributes to the
diversity of practice revealed in this study. Although it
would be unrealistic to expect the mere existence of a
guideline to change practice,39 it does seem reasonable
for GPs to expect that expert bodies will provide clear
guidance wherever possible. A community jury on PSA
testing reported men’s experiences of variable and
inconsistent advice from GPs, and recommended pro-
grammes to support GPs to provide patients with better
quality and consistent information about PSA screen-
ing.47 The Australian Medical Health and Research
Council (NHMRC) has recently produced an authorita-
tive summary of PSA testing beneﬁts and harms for GPs
to discuss with their patients.
The ﬁndings of this study offer important guidance
for the implementation of such recommendations in
practice. We recommend that agencies seeking to
promote the uptake of guidance for practitioners must
take account of the different motivations of GPs and rec-
ognise the signiﬁcant diversity in the approaches that
GPs are taking towards PSA testing of asymptomatic
men. GPs who employ heuristic 2, for example, were
already attentive to the epidemiological evidence, and so
are likely to be receptive to recent NHMRC guidance.
However, GPs who are employing heuristic 1 may need
very active knowledge translation strategies if they are to
change their practice. These GPs were deeply concerned
that by their failure to screen they might allow a man to
die of prostate cancer. It seems unlikely that they will
change their practice unless this concern is recognised
and responded to. Communications, workshops and new
incentives therefore need to consider variation in GP
perspectives and the range of drivers of current practice
as identiﬁed in this research (address legal concerns,
the need for consent due to potential harms and
acknowledge burden).
Limitations
Since physicians with strong opinions may have been
more likely to volunteer, some selection bias is possible.
However, diverse opinions and approaches were
reported, suggesting that strong selection bias is unlikely.
Conclusions
Future strategies for addressing the problem of prostate
cancer overdiagnosis in general practice should be
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underpinned by empirical evidence about how GPs
approach PSA testing, and the reasons they give for their
actions. Explicit consideration in practice guidelines of
the challenges faced by GPs when balancing underdiag-
nosis and overdiagnosis, including GPs experiences of
personal burden, medicolegal concerns and communi-
cation strategies, will better support GPs to inform and
guide men’s decisions on whether or not to have a PSA
test. Further public deliberation on how the inevitable
trade-offs could and should be managed in primary care
could also inform such discussions between clinicians
and their patients.48
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